Skip to main content Accessibility help
×
Home
Hostname: page-component-684899dbb8-pcn4s Total loading time: 0.557 Render date: 2022-05-17T11:36:43.295Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "useRatesEcommerce": false, "useNewApi": true }

The emerging biology of delusions

Published online by Cambridge University Press:  29 March 2010

G. K. Murray*
Affiliation:
Department of Psychiatry, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK
*
*Address for correspondence: G. K. Murray, Ph.D., Department of Psychiatry, University of Cambridge, Box 189, Addenbrooke's Hospital, CambridgeCB2 0QQ, UK. (Email: gm285@cam.ac.uk)
Rights & Permissions[Opens in a new window]

Abstract

This article examines a model of how delusions may arise, not just in schizophrenia but also in a number of neurological and psychiatric conditions, through a combination of dysregulated dopamine release from ascending midbrain pathways and reasoning bias. Negative symptoms may also be related to dopamine dysregulation, with the precise mixture of positive and negative symptoms depending on the relative degree of dopamine dysregulation in particular mesocorticolimbic circuits. Evidence for this model is examined, and predictions arising from this model are described.

Type
Editorial
Copyright
Copyright © Cambridge University Press 2010

Introduction

What do we know about the biology of delusions? Many theories have been advanced, and this article will address only a selected few. An important issue is that whilst the biology of delusions clearly relates to the biology of schizophrenia, the two are not identical or interchangeable. The biology of delusions, which tend to come and go in schizophrenia, must differ from the biological basis of the trait features of the disorder, and from the basis of the negative symptoms which tend to be longstanding (Makinen et al. Reference Makinen, Miettunen, Isohanni and Koponen2008). We know a lot about brain abnormalities (Ellison-Wright et al. Reference Ellison-Wright, Glahn, Laird, Thelen and Bullmore2008; Glahn et al. Reference Ellison-Wright, Glahn, Laird, Thelen and Bullmore2008) and cognitive deficits in schizophrenia (Nuechterlein et al. Reference Nuechterlein, Barch, Gold, Goldberg, Green and Heaton2004), for example, but this tells us very little about the biology of delusions.

Dopamine disturbance as a common pathway to psychosis, most proximal to the symptoms

Delusions occur in a variety of mental disorders: schizophreniform disorders, affective disorder (over 50% of bipolar disorder patients but under 15% in unipolar depression), Alzheimer's disease (20%), Parkinson's disease (13%) as well as in a number of rarer neurological conditions (Lyketsos et al. Reference Lyketsos, Steinberg, Tschanz, Norton, Steffens and Breitner2000; Ohayon & Schatzberg, Reference Ohayon and Schatzberg2002; Kennedy et al. Reference Kennedy, Everitt, Boydell, Van Os, Jones and Murray2005; Aarsland et al. Reference Aarsland, Bronnick, Ehrt, De Deyn, Tekin, Emre and Cummings2007). Do these conditions have anything biological in common? Is there, for example, a ‘final common pathway’ to psychosis? If there is one, it is likely to involve dopamine pathology, because there is overwhelming evidence from in vivo molecular imaging studies in patients that this is the neurotransmitter most closely associated with mental experience of psychosis. In a powerful series of experiments, Laruelle, Abi-Dargham and colleagues have shown that the degree of sensitization of the dopamine system is linked to the severity of psychotic symptoms (Parsey et al. Reference Parsey, Oquendo, Zea-Ponce, Rodenhiser, Kegeles, Pratap, Cooper, Van Heertum, Mann and Laruelle2001; Toda & Abi-Dargham, Reference Toda and Abi-Dargham2007). High presynaptic dopamine synthesis capacity is linked to the severity of psychotic symptoms not just in schizophrenia, but also in individuals with mild psychotic symptoms, such as hallucinations with preserved insight or suspicions (Abi-Dargham et al. Reference Abi-Dargham, Rodenhiser, Printz, Zea-Ponce, Gil, Kegeles, Weiss, Cooper, Mann, Van Heertum, Gorman and Laruelle2000; Laruelle et al. Reference Laruelle, Abi-Dargham, van Dyck, Gil, D'Souza, Erdos, McCance, Rosenblatt, Fingado, Zoghbi, Baldwin, Seibyl, Krystal, Charney and Innis1996; Breier et al. Reference Breier, Su, Saunders, Carson, Kolachana, de Bartolomeis, Weinberger, Weisenfeld, Malhotra, Eckelman and Pickar1997; Howes et al. Reference Howes, Montgomery, Asselin, Murray, Valli, Tabraham, Bramon-Bosch, Valmaggia, Johns, Broome, McGuire and Grasby2009). Of course, other transmitter abnormalities may be involved in schizophrenia – for example, γ-aminobutyric acid (GABA), glutamate and endocannabinoids – but this evidence is less direct, and disruptions in some of these neurotransmitter systems may be more closely linked to cognitive rather than psychotic manifestations of illness (Lewis et al. Reference Lewis, Hashimoto and Morris2008).

Influences on dopamine neurons

What could cause excessive dopamine synthesis or release in ascending midbrain systems? Some have speculated that the normal suppression of dopamine neuron firing by the frontal cortex is attenuated, but abnormality within the temporal lobe could also drive dopamine dysregulation. Schobel, Small and colleagues have recently shown that perfusion in the CA1 area of the hippocampus (which is important for recognizing salient, novel events), is increased in psychotic illness and in those with prodromal symptoms of psychosis (Schobel et al. Reference Schobel, Lewandowski, Corcoran, Moore, Brown, Malaspina and Small2009). We know, from work in experimental rodents by many scientists, including, notably, Grace, that hippocampal overactivity in CA1 can stimulate dopamine release from midbrain neurons via the hippocampal inputs to the striatum and from there to the dopamine neurons in the brainstem. The hippocampus, via GABAergic signals from the ventral pallidum, determines the number of dopamine neurons capable of responding to burst firing, and then glutamatergic afferents from cortical (prefrontal cortex) or subcortical structures, determine the degree of dopamine neuron firing (Lisman & Grace, Reference Lisman and Grace2005; Lodge & Grace, Reference Lodge and Grace2006; Goto et al. Reference Goto, Otani and Grace2007; Grace et al. Reference Grace, Floresco, Goto and Lodge2007). Preclinical models such as these have been extremely useful in suggesting how dopamine circuits might be disturbed in psychotic states, and how hippocampal pathology may drive this disturbance; nevertheless, it is critical that such models are eventually validated, refined or refuted by clinical studies.

A cross-level account of the biology of experience

If we accept a causal relationship between dopamine neurophysiology and psychosis, how can we understand the relationship between a molecule and mental experience? Miller has argued that the most powerful explanations in psychiatry are ‘cross-level’, in that they bridge scientific disciplines such as physiology and phenomenology (Miller, Reference Miller2008). In this respect, our task is to find an ‘experiential neuroscience’ of psychosis. We know that dopamine is important for movement, and perhaps also for mood (Nestler & Carlezon, Reference Nestler and Carlezon2006). What is less clear is why dopamine dysfunction in psychotic illness leads to paranoia, or hallucinations, and not to some other manifestation, such as mood disturbance or motor disturbance? A full understanding of the biology of psychosis requires an account of how brain disturbances lead to symptoms through intermediate psychological processes (Frith, Reference Frith1992; David, Reference David2006). It is only through this approach that we will we be able to answer the question of how a neurotransmitter disturbance provokes paranoid beliefs, and how and why a dopamine D2 receptor antagonist can improve such symptoms.

A plausible strategy in attempting to understand how dopamine dysfunction leads to delusions is to appeal to the normative function of dopamine systems in health. Dopamine's role in associative and reinforcement learning (Robbins & Everitt, Reference Robbins and Everitt1996; Schultz et al. Reference Schultz, Dayan and Montague1997; Pessiglione et al. Reference Pessiglione, Seymour, Flandin, Dolan and Frith2006) has potential relevance for the biology of psychosis. As Miller stated in 1976:

The process of acquiring the associations necessary for learning a conditioned response in an experimental animal depends on the presence of dopamine. In human schizophrenic patients, an excessive supply of cerebral dopamine may facilitate the acquisition of associations between ‘units of information’, to the point where unrelated features are associated and treated as if they are meaningful combinations: this process can be terminated by administering dopamine antagonists. (Miller, Reference Miller1976)

The argument has been subsequently developed by several scholars (Beninger, Reference Beninger1983; McKenna, Reference McKenna1987; Gray et al. Reference Gray, Feldon, Rawlins and Smith1991; Kapur, Reference Kapur2003), but until recently has there been little evidence for associative or reinforcement learning abnormalities in psychosis, let alone evidence to specifically link such processes to symptoms. However, we do now know that there are associative learning deficits in schizophrenia and first-episode psychosis, including deficits in causal learning, probabilistic learning and reversal learning (Corlett et al. Reference Corlett, Murray, Honey, Aitken, Shanks, Robbins, Bullmore, Dickinson and Fletcher2007; Waltz & Gold, Reference Waltz and Gold2007; Murray et al. Reference Murray, Cheng, Clark, Barnett, Blackwell, Fletcher, Robbins, Bullmore and Jones2008 a). Abnormalities in reward processing in schizophrenia can be exacerbated by medication (Schlagenhauf et al. Reference Schlagenhauf, Juckel, Koslowski, Kahnt, Knutson, Dembler, Kienast, Gallinat, Wrase and Heinz2008), but deficits are also present in patients who are not taking dopamine receptor antagonists (Murray et al. Reference Murray, Clark, Corlett, Blackwell, Cools, Jones, Robbins and Poustka2008 b). Furthermore, in schizophrenia, learning about important events is linked with dysfunction in dopaminergic regions such as the striatum and midbrain (Jensen et al. Reference Jensen, Willeit, Zipursky, Savina, Smith, Menon, Crawley and Kapur2008; Murray et al. Reference Murray, Corlett, Clark, Pessiglione, Blackwell, Honey, Jones, Bullmore, Robbins and Fletcher2008 c). Frontal, temporal and parietal cortical abnormalities are also seen in such processes (Murray et al. Reference Murray, Corlett, Clark, Pessiglione, Blackwell, Honey, Jones, Bullmore, Robbins and Fletcher2008 c, Reference Murray, Corlett and Fletcher2010), and recent evidence suggests that the degree of abnormality of cortical response is linked to the severity of delusional ideation (Corlett et al. Reference Corlett, Murray, Honey, Aitken, Shanks, Robbins, Bullmore, Dickinson and Fletcher2007; Schlagenhauf et al. Reference Schlagenhauf, Sterzer, Schmack, Ballmaier, Rapp, Wrase, Juckel, Gallinat and Heinz2009).

How do delusions persist?

Is the biology of the genesis of a delusion the same as the biology of a longstanding delusion? Miller has called longstanding delusions ‘cognitive habits’. Like many false beliefs, they can persist in the absence of any pathophysiology. This fact has major implications for studies of psychosis patients where researchers attempt to correlate delusional strength with a physiological measure. Many of us believe things that are false just because we made up our minds about them many years ago. In my view, we need a biology of the genesis of delusions, and a psychology of how they persist. The two processes may be at least partially separable. Kapur and colleagues have shown that administration of a dopamine receptor antagonist does attenuate the strength of psychotic symptoms with rapid onset, but that the process of complete resolution of delusions follows a slower course, with patients first being less captivated by their delusions, and then gradually being less and less bothered by them over time (Agid et al. Reference Agid, Kapur, Arenovich and Zipursky2003, Reference Agid, Kapur, Warrington, Loebel and Siu2008; Kapur et al. Reference Kapur, Arenovich, Agid, Zipursky, Lindborg and Jones2005; Mizrahi et al. Reference Mizrahi, Bagby, Zipursky and Kapur2005, Reference Mizrahi, Kiang, Mamo, Arenovich, Bagby, Zipursky and Kapur2006). Thus, delusions resolve in two related processes. There is an important cognitive and logical reasoning operation to perform in dismantling a delusional system, which inevitably takes time and may not be closely related to any particular neuromodulatory chemical. However, given that patients with schizophrenia have reasonable logical reasoning (Owen et al. Reference Owen, Cutting and David2007) there is likely to be another factor involved which must be addressed before a delusion becomes amenable to logical scrutiny. This key factor is the motivational salience of the abnormal thought, and this factor can be addressed with medication (Kapur, Reference Kapur2003).

A two-factor account of delusions

The above conceptualisation relates to what is sometimes termed a ‘two-factor’ account of delusions. Coltheart (Reference Coltheart2007), whose work is mainly grounded in studies of patients with monothematic delusions secondary to brain lesions or dementia, identifies the two factors: how does the delusion arise, and how does it persist? A closely related model perhaps more relevant to psychosis in young adults at least (but possibly also relevant for psychosis in other groups of patients) is that one abnormality is required to generate perceptual abnormalities or unusual thoughts or experiences, such as feelings of paranoia, coincidence or significance, and another abnormality is required to move from unusual thoughts into delusions. Thus I would rephrase Coltheart's questions as ‘how does the unusual idea/experience arise, and how does it change from an unusual thought to a delusion?’ Having experienced something unusual, an individual can then interpret it in a number of ways. It is possible he may recognize that he has experienced something unusual, that his mind is playing tricks on him, and that he can seek help for this phenomenon. Such an individual would probably be diagnosed as having an ‘at-risk mental state’ if he presented to a ‘prodromal’ clinic (Yung et al. Reference Yung, Phillips and McGorry2004). If he did not seek help and did not find the experiences distressing, he might never come to the attention of medical services but, if he also exhibited introverted anhedonia, then he might be considered to have a schizotypal personality (van Os, Reference van Os2003).

An alternative possibility is that such an individual might draw bizarre conclusions to try and explain his strange experiences: he might deduce from repeatedly noticing policemen that he is under surveillance and is being persecuted, or deduce from hearing voices that there is a transmitter in his head. Not everyone who experiences hallucinations develops a psychotic illness or a delusional interpretation of their hallucination (Sommer et al. Reference Sommer, Daalman, Rietkerk, Diederen, Bakker, Wijkstra and Boks2008). Studies of reasoning in schizophrenia and other psychoses have demonstrated intact logical reasoning but impaired probabilistic reasoning. A two-factor account of delusions states that one abnormality is required to experience prodromal symptoms, and a deficit in reasoning is required to explain what has been termed the ‘jump to conclusions’ (Garety et al. Reference Garety, Hemsley and Wessely1991) exhibited by some patients with delusions. The two deficits may have some overlap in their biological basis, but this is not a necessary part of the account. The reasoning deficit could be in either logical or probabilistic reasoning, with the evidence favouring the latter (Garety et al. Reference Garety, Hemsley and Wessely1991, Reference Garety, Bebbington, Fowler, Freeman and Kuipers2007; Owen et al. Reference Owen, Cutting and David2007).

This understanding yields the following predictions: individuals with longstanding stable delusional disorder will show less abnormal dopamine synthesis than individuals with prodromal symptoms of schizophrenia such as newly formed attenuated delusions (referential ideas). Patients with longstanding delusions which have been attenuated by dopamine antagonists may well no longer have any dopaminergic pathology [as could be examined in vivo with positron emission tomography (PET) or single photon emission computed tomography (SPECT) molecular imaging] but should show reasoning abnormalities. Thus, when conducting experiments that attempt to relate symptoms with physiological measures it is important to bear in mind whether patients are in the process of developing delusions, or whether their delusions are merely cognitive habits that persist in the context of a subsequently normalized physiology (Chouinard & Miller, Reference Chouinard and Miller1999a, Reference Chouinard and Millerb).

An alternative to the two-factor model of delusions

Fletcher & Frith (Reference Fletcher and Frith2009) have argued that a two-stage theory of psychosis in schizophrenia is unnecessary, as both perception and belief rely on predictions and updating those predictions in the light of evidence (so-called prediction error). Frith has shown the importance in health of being able to monitor one's own thoughts and actions subconsciously, and of being able to predict the consequences of those actions using the so-called efference-copy or corollary discharge mechanism. He and others have shown that patients with schizophrenia do indeed have problems in predictive coding and monitoring of their actions (Feinberg, Reference Feinberg1978; McGuire et al. Reference McGuire, Silbersweig, Wright, Murray, David, Frackowiak and Frith1995; Shergill et al. Reference Shergill, Samson, Bays, Frith and Wolpert2005; Mathalon & Ford, Reference Mathalon and Ford2008). By linking this theory of abnormal predictive coding in psychosis to evidence that dopamine-driven prediction error signalling is also abnormal in psychosis, Fletcher and Frith argue that abnormal predictive coding at multiple levels of brain complexity could lead to both false perceptions and false beliefs in schizophrenia. This provides a unitary psychological process that could underlie all positive psychotic symptoms. This simplicity and parsimony is a very attractive aspect of the theory; a disadvantage is that this parsimony may not be reflected at a biological level. For example, it is unlikely that a single neurotransmitter system could be responsible for predictive coding throughout the brain. Whilst predictive coding for rewards may be intricately linked to dopamine, it is unlikely that predictive coding for visual perception will have the same biological basis. Empirical work combining pharmacological, imaging and psychological studies is required to test this theory.

A possible link to negative symptoms

A longstanding problematic issue in schizophrenia is the paradox of how an individual can have both positive and negative symptoms at the same time. A full account of psychosis would explain how these symptoms co-occur in many, though not all, individuals. One possibility that has been previously suggested is that the same neural monoaminergic system could be responsible for both positive and negative symptoms. Stein & Wise (Reference Stein and Wise1971) argued that dysregulation of noradrenalin's role in reward processing could result in both positive and negative symptoms, but given the progress we have made in understanding dopamine's role in incentive motivation and in psychotic illness, their theory should perhaps now be reformulated in terms of dopamine dysregulation.

It is true that there is an apparent conflict in attempting to explain both positive and negative symptoms through disturbance of the same psychological construct of incentive motivation. If the incentive motivation system is down-regulated, the result should be an apathetic individual, without positive symptoms; if it is hyperactive, everything should be imbued with motivational importance (perhaps as in a manic state). Perhaps the resolution to this paradox is in the system's potential dysregulation, rather than simple over-activation or under-activation of the system. In a dysregulated system, a stimulus that should be an incentive may in fact lack motivational value, and stimuli that should be valueless may take on motivational significance.

At the biological level, there could be at least two possible explanations for how disruption of dopamine systems could lead to both positive and negative symptoms. One possibility is that the dopaminergic system could be temporally dysregulated; the dopamine neurons could be overactive inappropriately, resulting in aberrant assignment of motivational salience to irrelevant phenomena, and they could be underactive inappropriately, failing to fire to primary rewards or cues predictive of primary rewards. Another possibility is that there could be anatomical subsystems that display different pathologies in psychotic illness. The so-called ‘limbic striatum’, or ventro-medial striatal system, has been especially linked to reward associations, and could be more implicated in negative symptoms if underactive, whilst the more dorsolateral (‘associative’) striatal system could be more related to positive symptoms, and this could be overactive. There is some evidence to suggest that positive psychotic symptoms are linked specifically to dopaminergic abnormalities in the head of the caudate nucleus, i.e. the ‘associative’ striatum (Kegeles et al. Reference Kegeles, Frankle, Gil, Talbot, Narendran, Silfstein, Huang, Hwang, Cangianio, Cooper, Haber, Abi-Dargham and Laruelle2007; Howes et al. Reference Howes, Montgomery, Asselin, Murray, Valli, Tabraham, Bramon-Bosch, Valmaggia, Johns, Broome, McGuire and Grasby2009). If it could be shown that patients with prominent negative symptoms but no positive symptoms have normal associative striatal dopamine function, but abnormal limbic striatal dopamine, then this would be strong evidence for the anatomical subsystem hypothesis.

Conclusion

Developments in preclinical science have paved the way for plausible explanatory models to link biological disturbances to disturbed experiences in psychosis (Corlett et al. Reference Corlett, Krystal, Taylor and Fletcher2009; Murray & Fletcher, Reference Murray, Fletcher, Dreher and Tremblay2009; Ziauddeen & Murray, Reference Ziauddeen and Murray2010). How delusions arise, not just in schizophrenia but also in other disorders, can be accounted for by a combination of dysregulated firing in ascending midbrain dopamine neurons and reasoning bias. Negative symptoms may be related to dopamine dysregulation, perhaps especially in circuits involving the limbic or ventral striatum, with the precise mixture of positive and negative symptoms in an individual depending on the relative degree of dopamine dysregulation in particular mesocorticostriatal circuits. A more precise understanding of the relationship between biology and mental experience will not only prove immensely valuable in psychoeducational interventions with patients and carers, but it will also facilitate the development of better treatments for psychotic symptoms in a variety of disorders (Mallet et al. Reference Mallet, Schupbach, N'Diaye, Remy, Bardinet, Czernecki, Welter, Pelissolo, Ruberg, Agid and Yelnik2007, Reference Mallet, Polosan, Jaafari, Baup, Welter, Fontaine, du Montcel, Yelnik, Chereau, Arbus, Raoul, Aouizerate, Damier, Chabardes, Czernecki, Ardouin, Krebs, Bardinet, Chaynes, Burbaud, Cornu, Derost, Bougerol, Bataille, Mattei, Dormont, Devaux, Verin, Houeto, Pollak, Benabid, Agid, Krack, Millet and Pelissolo2008; Murray & Fletcher, Reference Murray, Fletcher, Dreher and Tremblay2009).

Acknowledgements

Graham Murray is supported by a Medical Research Council Clinician Scientist Fellowship Award and a NARSAD Young Investigator Award.

Declaration of Interest

None.

References

Aarsland, D, Bronnick, K, Ehrt, U, De Deyn, PP, Tekin, S, Emre, M, Cummings, JL (2007). Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. Journal of Neurology, Neurosurgery and Psychiatry 78, 3642.CrossRefGoogle ScholarPubMed
Abi-Dargham, A, Rodenhiser, J, Printz, D, Zea-Ponce, Y, Gil, R, Kegeles, LS, Weiss, R, Cooper, TB, Mann, JJ, Van Heertum, RL, Gorman, JM, Laruelle, M (2000). Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proceedings of the National Academy of Sciences USA 97, 81048109.CrossRefGoogle Scholar
Agid, O, Kapur, S, Arenovich, T, Zipursky, RB (2003). Delayed-onset hypothesis of antipsychotic action. A hypothesis tested and rejected. Archives of General Psychiatry 60, 12281235.CrossRefGoogle Scholar
Agid, O, Kapur, S, Warrington, L, Loebel, A, Siu, C (2008). Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disorders. Schizophrenia Research 102, 241248.CrossRefGoogle ScholarPubMed
Beninger, RJ (1983). The role of dopamine in locomotor activity and learning. Brain Research 287, 173196.CrossRefGoogle Scholar
Breier, A, Su, TP, Saunders, R, Carson, RE, Kolachana, BS, de Bartolomeis, A, Weinberger, DR, Weisenfeld, N, Malhotra, AK, Eckelman, WC, Pickar, D (1997). Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proceedings of the National Academy of Sciences USA 94, 25692574.CrossRefGoogle ScholarPubMed
Chouinard, G, Miller, R (1999 a). A rating scale for psychotic symptoms (RSPS) part I: theoretical principles and subscale 1: perception symptoms (illusions and hallucinations). Schizophrenia Research 38, 101122.CrossRefGoogle Scholar
Chouinard, G, Miller, R (1999 b). A rating scale for psychotic symptoms (RSPS): part II: subscale 2: distraction symptoms (catatonia and passivity experiences subscale 3: delusions and semi-structured interview (SSCI-RSPS). Schizophrenia Research 38, 123150.CrossRefGoogle Scholar
Coltheart, M (2007). Cognitive neuropsychiatry and delusional belief. Quarterly Journal of Experimental Psychology 60, 10411062.CrossRefGoogle ScholarPubMed
Corlett, PR, Krystal, JH, Taylor, JR, Fletcher, PC (2009). Why do delusions persist? Frontiers in Human Neuroscience 3, 12.CrossRefGoogle ScholarPubMed
Corlett, PR, Murray, GK, Honey, GD, Aitken, MR, Shanks, DR, Robbins, TW, Bullmore, ET, Dickinson, A, Fletcher, PC (2007). Disrupted prediction-error signal in psychosis: evidence for an associative account of delusions. Brain 130, 23872400.CrossRefGoogle ScholarPubMed
David, AS (2006). A method for studies of madness. Cortex 42, 921925.CrossRefGoogle ScholarPubMed
Ellison-Wright, I, Glahn, DC, Laird, AR, Thelen, SM, Bullmore, E (2008). The anatomy of first-episode and chronic schizophrenia: an anatomical likelihood estimation meta-analysis. American Journal of Psychiatry 165, 10151023.CrossRefGoogle ScholarPubMed
Feinberg, I (1978). Efference copy and corollary discharge: implications for thinking and its disorders. Schizophrenia Bulletin 4, 636640.CrossRefGoogle ScholarPubMed
Fletcher, PC, Frith, CD (2009). Perceiving is believing: a Bayesian approach to explaining the positive symptoms of schizophrenia. Nature Reviews Neuroscience 10, 4858.CrossRefGoogle ScholarPubMed
Frith, CD (1992). The Cognitive Neuropsychology of Schizophrenia. Taylor and Francis: Hove, UK.Google Scholar
Garety, PA, Bebbington, P, Fowler, D, Freeman, D, Kuipers, E (2007). Implications for neurobiological research of cognitive models of psychosis: a theoretical paper. Psychological Medicine 37, 13771391.CrossRefGoogle ScholarPubMed
Garety, PA, Hemsley, DR, Wessely, S (1991). Reasoning in deluded schizophrenic and paranoid patients. Biases in performance on a probabilistic inference task. Journal of Nervous and Mental Disease 179, 194201.CrossRefGoogle ScholarPubMed
Glahn, DC, Laird, AR, Ellison-Wright, I, Thelen, SM, Robinson, JL, Lancaster, JL, Bullmore, E, Fox, PT (2008). Meta-analysis of gray matter anomalies in schizophrenia: application of anatomic likelihood estimation and network analysis. Biological Psychiatry 64, 774781.CrossRefGoogle ScholarPubMed
Goto, Y, Otani, S, Grace, AA (2007). The Yin and Yang of dopamine release: a new perspective. Neuropharmacology 53, 583587.CrossRefGoogle ScholarPubMed
Grace, AA, Floresco, SB, Goto, Y, Lodge, DJ (2007). Regulation of firing of dopaminergic neurons and control of goal-directed behaviors. Trends in Neurosciences 30, 220227.CrossRefGoogle ScholarPubMed
Gray, JA, Feldon, J, Rawlins, JNP, Smith, AD (1991). The neuropsychology of schizophrenia. Behavior and Brain Sciences 14, 119.CrossRefGoogle Scholar
Howes, OD, Montgomery, AJ, Asselin, MC, Murray, RM, Valli, I, Tabraham, P, Bramon-Bosch, E, Valmaggia, L, Johns, L, Broome, M, McGuire, PK, Grasby, PM (2009). Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Archives of General Psychiatry 66, 1320.CrossRefGoogle ScholarPubMed
Jensen, J, Willeit, M, Zipursky, RB, Savina, I, Smith, AJ, Menon, M, Crawley, AP, Kapur, S (2008). The formation of abnormal associations in schizophrenia: neural and behavioral evidence. Neuropsychopharmacology 33, 473479.CrossRefGoogle ScholarPubMed
Kapur, S (2003). Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. American Journal of Psychiatry 160, 1323.CrossRefGoogle Scholar
Kapur, S, Arenovich, T, Agid, O, Zipursky, R, Lindborg, S, Jones, B (2005). Evidence for onset of antipsychotic effects within the first 24 hours of treatment. American Journal of Psychiatry 162, 939946.CrossRefGoogle Scholar
Kegeles, L, Frankle, WG, Gil, R, Talbot, PS, Narendran, R, Silfstein, M, Huang, Y, Hwang, DR, Cangianio, C, Cooper, TB, Haber, SN, Abi-Dargham, A, Laruelle, M (2007). Schizophrenia is associated with increased synaptic dopamine in associative rather than limbic striatum: implications for mechanism of action of antipsychotic drugs. Schizophrenia Bulletin 33, 294.Google Scholar
Kennedy, N, Everitt, B, Boydell, J, Van Os, J, Jones, PB, Murray, RM (2005). Incidence and distribution of first-episode mania by age: results from a 35-year study. Psychological Medicine 35, 855863.CrossRefGoogle ScholarPubMed
Laruelle, M, Abi-Dargham, A, van Dyck, CH, Gil, R, D'Souza, CD, Erdos, J, McCance, E, Rosenblatt, W, Fingado, C, Zoghbi, SS, Baldwin, RM, Seibyl, JP, Krystal, JH, Charney, DS, Innis, RB (1996). Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proceedings of the National Academy of Sciences USA 93, 92359240.CrossRefGoogle ScholarPubMed
Lewis, DA, Hashimoto, T, Morris, HM (2008). Cell and receptor type-specific alterations in markers of GABA neurotransmission in the prefrontal cortex of subjects with schizophrenia. Neurotoxocity Research 14, 237248.CrossRefGoogle ScholarPubMed
Lisman, JE, Grace, AA (2005). The hippocampal–VTA loop: controlling the entry of information into long-term memory. Neuron 46, 703713.CrossRefGoogle ScholarPubMed
Lodge, DJ, Grace, AA (2006). The hippocampus modulates dopamine neuron responsivity by regulating the intensity of phasic neuron activation. Neuropsychopharmacology 31, 13561361.CrossRefGoogle ScholarPubMed
Lyketsos, CG, Steinberg, M, Tschanz, JT, Norton, MC, Steffens, DC, Breitner, JC (2000). Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. American Journal of Psychiatry 157, 708714.CrossRefGoogle Scholar
Makinen, J, Miettunen, J, Isohanni, M, Koponen, H (2008). Negative symptoms in schizophrenia: a review. Nordic Journal of Psychiatry 62, 334341.CrossRefGoogle ScholarPubMed
Mallet, L, Polosan, M, Jaafari, N, Baup, N, Welter, ML, Fontaine, D, du Montcel, ST, Yelnik, J, Chereau, I, Arbus, C, Raoul, S, Aouizerate, B, Damier, P, Chabardes, S, Czernecki, V, Ardouin, C, Krebs, MO, Bardinet, E, Chaynes, P, Burbaud, P, Cornu, P, Derost, P, Bougerol, T, Bataille, B, Mattei, V, Dormont, D, Devaux, B, Verin, M, Houeto, JL, Pollak, P, Benabid, AL, Agid, Y, Krack, P, Millet, B, Pelissolo, A (2008). Subthalamic nucleus stimulation in severe obsessive-compulsive disorder. New England Journal of Medicine 359, 21212134.CrossRefGoogle ScholarPubMed
Mallet, L, Schupbach, M, N'Diaye, K, Remy, P, Bardinet, E, Czernecki, V, Welter, ML, Pelissolo, A, Ruberg, M, Agid, Y, Yelnik, J (2007). Stimulation of subterritories of the subthalamic nucleus reveals its role in the integration of the emotional and motor aspects of behavior. Proceedings of the National Academy of Sciences USA 104, 1066110666.CrossRefGoogle ScholarPubMed
Mathalon, DH, Ford, JM (2008). Corollary discharge dysfunction in schizophrenia: evidence for an elemental deficit. Clinical EEG Neuroscience 39, 8286.CrossRefGoogle ScholarPubMed
McGuire, PK, Silbersweig, DA, Wright, I, Murray, RM, David, AS, Frackowiak, RS, Frith, CD (1995). Abnormal monitoring of inner speech: a physiological basis for auditory hallucinations. Lancet 346, 596600.CrossRefGoogle ScholarPubMed
McKenna, PJ (1987). Pathology, phenomenology and the dopamine hypothesis of schizophrenia. British Journal of Psychiatry 151, 288301.CrossRefGoogle ScholarPubMed
Miller, R (1976). Schizophrenic psychology, associative learning and the role of forebrain dopamine. Medical Hypotheses 2, 203211.CrossRefGoogle ScholarPubMed
Miller, R (2008). A Neurodynamic Theory of Schizophrenia. Lulu: New Zealand.Google Scholar
Mizrahi, R, Bagby, RM, Zipursky, RB, Kapur, S (2005). How antipsychotics work: the patients' perspective. Progress in Neuro-Psychopharmacology and Biological Psychiatry 29, 859864.CrossRefGoogle ScholarPubMed
Mizrahi, R, Kiang, M, Mamo, DC, Arenovich, T, Bagby, RM, Zipursky, RB, Kapur, S (2006). The selective effect of antipsychotics on the different dimensions of the experience of psychosis in schizophrenia spectrum disorders. Schizophrenia Research 88, 111118.CrossRefGoogle ScholarPubMed
Murray, GK, Cheng, F, Clark, L, Barnett, JH, Blackwell, AD, Fletcher, PC, Robbins, TW, Bullmore, ET, Jones, PB (2008 a). Reinforcement and reversal learning in first-episode psychosis. Schizophrenia Bulletin 34, 848855.CrossRefGoogle ScholarPubMed
Murray, GK, Clark, L, Corlett, PR, Blackwell, AD, Cools, R, Jones, PB, Robbins, TW, Poustka, L (2008 b). Incentive motivation in first-episode psychosis: a behavioural study. BMC Psychiatry 8, 34.CrossRefGoogle ScholarPubMed
Murray, GK, Corlett, PR, Clark, L, Pessiglione, M, Blackwell, AD, Honey, G, Jones, PB, Bullmore, ET, Robbins, TW, Fletcher, PC (2008 c). Substantia nigra/ventral tegmental reward prediction error disruption in psychosis. Molecular Psychiatry 13, 239, 267276.CrossRefGoogle ScholarPubMed
Murray, GK, Corlett, PR, Fletcher, PC (2010). The neural underpinnings of associative learning in health and psychosis: how can performance be preserved when brain responses are abnormal? Schizophrenia Bulletin. Published online: 12 February 2010. doi:10.1093/schbul/sbq005.CrossRefGoogle ScholarPubMed
Murray, GK, Fletcher, PC (2009). Can models of reinforcement learning help us to understand symtpoms of schizophrenia? In Handbook of Reward and Decision-Making (ed. Dreher, J.-C. and Tremblay, L.), pp. 251269. Elsevier: Oxford.Google Scholar
Nestler, EJ, Carlezon, WA Jr. (2006). The mesolimbic dopamine reward circuit in depression. Biological Psychiatry 59, 11511159.CrossRefGoogle ScholarPubMed
Nuechterlein, KH, Barch, DM, Gold, JM, Goldberg, TE, Green, MF, Heaton, RK (2004). Identification of separable cognitive factors in schizophrenia. Schizophrenia Research 72, 2939.CrossRefGoogle Scholar
Ohayon, MM, Schatzberg, AF (2002). Prevalence of depressive episodes with psychotic features in the general population. American Journal of Psychiatry 159, 18551861.CrossRefGoogle ScholarPubMed
Owen, GS, Cutting, J, David, AS (2007). Are people with schizophrenia more logical than healthy volunteers? British Journal of Psychiatry 191, 453454.CrossRefGoogle ScholarPubMed
Parsey, RV, Oquendo, MA, Zea-Ponce, Y, Rodenhiser, J, Kegeles, LS, Pratap, M, Cooper, TB, Van Heertum, R, Mann, JJ, Laruelle, M (2001). Dopamine D(2) receptor availability and amphetamine-induced dopamine release in unipolar depression. Biological Psychiatry 50, 313322.CrossRefGoogle ScholarPubMed
Pessiglione, M, Seymour, B, Flandin, G, Dolan, RJ, Frith, CD (2006). Dopamine-dependent prediction errors underpin reward-seeking behaviour in humans. Nature 442, 10421045.CrossRefGoogle ScholarPubMed
Robbins, TW, Everitt, BJ (1996). Neurobehavioural mechanisms of reward and motivation. Current Opinion in Neurobiology 6, 228236.CrossRefGoogle ScholarPubMed
Schlagenhauf, F, Juckel, G, Koslowski, M, Kahnt, T, Knutson, B, Dembler, T, Kienast, T, Gallinat, J, Wrase, J, Heinz, A (2008). Reward system activation in schizophrenic patients switched from typical neuroleptics to olanzapine. Psychopharmacology 196, 673684.CrossRefGoogle ScholarPubMed
Schlagenhauf, F, Sterzer, P, Schmack, K, Ballmaier, M, Rapp, M, Wrase, J, Juckel, G, Gallinat, J, Heinz, A (2009). Reward feedback alterations in unmedicated schizophrenia patients: relevance for delusions. Biological Psychiatry 65, 10321039.CrossRefGoogle ScholarPubMed
Schobel, SA, Lewandowski, NM, Corcoran, CM, Moore, H, Brown, T, Malaspina, D, Small, SA (2009). Differential targeting of the CA1 subfield of the hippocampal formation by schizophrenia and related psychotic disorders. Archives of General Psychiatry 66, 938946.CrossRefGoogle ScholarPubMed
Schultz, W, Dayan, P, Montague, PR (1997). A neural substrate of prediction and reward. Science 275, 15931599.CrossRefGoogle ScholarPubMed
Shergill, SS, Samson, G, Bays, PM, Frith, CD, Wolpert, DM (2005). Evidence for sensory prediction deficits in schizophrenia. American Journal of Psychiatry 162, 23842386.CrossRefGoogle Scholar
Sommer, IE, Daalman, K, Rietkerk, T, Diederen, KM, Bakker, S, Wijkstra, J, Boks, MP (2008). Healthy individuals with auditory verbal hallucinations; who are they? Psychiatric assessments of a selected sample of 103 subjects. Schizophrenia Bulletin. Published online: 9 October 2008. doi:10.1093/schbul/sbn130.Google ScholarPubMed
Stein, L, Wise, CD (1971). Possible etiology of schizophrenia: progressive damage to the noradrenergic reward system by 6-hydroxydopamine. Science 171, 10321036.CrossRefGoogle ScholarPubMed
Toda, M, Abi-Dargham, A (2007). Dopamine hypothesis of schizophrenia: making sense of it all. Current Psychiatry Reports 9, 329336.CrossRefGoogle Scholar
van Os, J (2003). Is there a continuum of psychotic experiences in the general population? Epidemiologia e Psichiatria Sociale 12, 242252.CrossRefGoogle Scholar
Waltz, JA, Gold, JM (2007). Probabilistic reversal learning impairments in schizophrenia: further evidence of orbitofrontal dysfunction. Schizophrenia Research 93, 296303.CrossRefGoogle ScholarPubMed
Yung, A, Phillips, L, McGorry, P (2004). Treating Schizophrenia in the Prodromal Phase. Martin Dunitz: Basingstoke, UK.CrossRefGoogle Scholar
Ziauddeen, H, Murray, GK (2010). The relevance of reward pathways for schizophrenia. Current Opinion in Psychiatry 23, 9196.CrossRefGoogle Scholar
You have Access
17
Cited by

Save article to Kindle

To save this article to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

The emerging biology of delusions
Available formats
×

Save article to Dropbox

To save this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about saving content to Dropbox.

The emerging biology of delusions
Available formats
×

Save article to Google Drive

To save this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about saving content to Google Drive.

The emerging biology of delusions
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *